Colorectal Carcinoma Clinical Trial
— ADOPTIONVerified date | August 2015 |
Source | Technische Universität München |
Contact | n/a |
Is FDA regulated | No |
Health authority | Germany: Ethics Commission |
Study type | Observational |
Adenomas and hyperplastic polyps are polypoid lesion and may occur at any location in the
colon. At the present moment, all polyps should be resected endoscopically, although only
adenomas, but not hyperplastic polyps have the potential to develop colorectal cancer. This
approach enables the conduction of microscopic investigations of the lesions. By today, only
the pathological diagnosis can distinguish exactly between adenomas and hyperplastic polyps.
Some studies have investigated the value of the socalled optical biopsy method. Optical
biopsy means the visual assessment of the polyp and the determination of a diagnosis solely
on behalf of optical criteria. This method is conducted in real time during colonoscopy. If
it can be shown, that endoscopist using optical biopsy are able to predict histopathological
diagnoses of colonic polyps sufficiently this would possibly lead to simplification of
diagnostic procedures. For instance, it would be conceivable to resect hyperplastic polyps
and small adenomas and discard them without further assessment by a pathologist.
Gastroenterological societies demand for a 90 percent accordance between diagnoses set by
endoscopists and pathologists as a prerequisite for the implementation of the optical biopsy
method.
In this study we want to proof that the use of a new narrow-band imaging (NBI) tool (Exera
III, Olmpus) is capable to rise accuracy of optically ascertained diagnoses of colonic
polyps. NBI is a light filter tool which can be activated by pressing a button at the
endoscope. NBI function leads to an endoscopic picture which appears blue and enables
endoscopists to better assess surface structures and vascular patterns.
In a prospective randomised multicenter setting we plan to conduct colonoscopy in 380
patients. Half of the patients will be examined without use of NBI (control arm). In these
cases colonoscopists will assess optical diagnosis of polyps without turning on the NBI
tool. If polyps are detected in patients belonging to the intervention arm NBI will be used
and optical diagnosis will be determined using the NICE (NBI International Colorectal
Endoscopic) classification. All polyps will be resected and send to pathology for further
microscopic assessment. After completing the trial we aim to compare accuracy of the optical
diagnosis in both groups. Our hypothesis is, that by using the new NBI tool accuracy
(accordance between optical and histopathological diagnosis) can be increased from 78% to
90%.
Status | Completed |
Enrollment | 380 |
Est. completion date | May 2015 |
Est. primary completion date | April 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: - medical indication for colonoscopy - age >18 years - written consent given by patient Exclusion Criteria: - age < 18 years - patients denying written consent - pregnant women - ASA class IV, V and VI - known contraindication for polyp resection - indication for colonoscopy: preknown adenoma/polyp/carcinoma - indication for colonoscopy: emergency (e.g. severe rectal bleeding) |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Germany | Innere Medizin I am Sana Klinikum Lichtenberg | Berlin | |
Germany | Medizinische Klinik I des Universitätsklinikums Frankfurt | Frankfurt am Main | Hessen |
Germany | II Medizinische Klinik am Klinikum rechts der Isar der Technischen Universität München | Munich | Bayern |
Lead Sponsor | Collaborator |
---|---|
Technische Universität München | Olympus |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Accuracy optical biopsy | After obtaining the histopathological diagnosis of resected polyps (approximately 3 days - 2 weeks after colonoscopy ) accuracy of optical diagnosis can be determined | up to 2 weeks (participants will be followed for the duration of hospital stay or outpatient treatment, an expected average of 2 weeks) | No |
Secondary | Adenoma detection rate | up to 2 weeks (participants will be followed for the duration of hospital stay or outpatient treatment, an expected average of 2 weeks) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04444232 -
Cancer Communication Within Hispanic Social Networks
|
N/A | |
Recruiting |
NCT06233253 -
Online Mindfulness-Based Intervention to Decrease Pre-Procedural Anxiety Before a First-Time Screening Colonoscopy
|
N/A | |
Recruiting |
NCT05799820 -
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
|
Phase 2 | |
Recruiting |
NCT04666727 -
Role of Diet on the Microbiome of the Digestive System
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Recruiting |
NCT02376452 -
Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients
|
Phase 2 | |
Completed |
NCT02254486 -
Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults
|
Phase 3 | |
Completed |
NCT01486251 -
Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer
|
N/A | |
Terminated |
NCT01233544 -
Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases
|
Phase 3 | |
Recruiting |
NCT02073500 -
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
|
||
Completed |
NCT00704600 -
Nelfinavir, a Phase I/Phase II Rectal Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00485316 -
Laparoscopic Assisted Versus Open Resection for Colorectal Carcinoma
|
Phase 3 | |
Recruiting |
NCT04430738 -
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
|
Phase 1/Phase 2 | |
Terminated |
NCT02669914 -
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
|
Phase 2 | |
Completed |
NCT05022511 -
Three Birds With One Stone
|
N/A | |
Completed |
NCT04607291 -
Health Service Intervention for the Improvement of Access and Adherence to Colorectal Cancer Screening
|
Phase 1 | |
Not yet recruiting |
NCT03969784 -
Microparticles in Peritoneal Carcinomatosis of Colorectal Origin
|
N/A | |
Not yet recruiting |
NCT05630794 -
Testing ONC201 to Prevent Colorectal Cancer
|
Phase 1 | |
Terminated |
NCT05291988 -
A Multilevel Approach for Improvement in Screening of Colorectal Cancer in Rural Communities, The Screen to Save Trial
|
N/A | |
Suspended |
NCT04108481 -
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
|
Phase 1/Phase 2 |